ADIL - Wutah dodolan YoY (TTM) adialpharma.com

Logo grafis adialpharma.com (ADIL)

Adial Pharmaceuticals independently conducts final confirmatory tests of its developments, collaborating only with research centers. Future revenue is based on the market launch of an innovative alcoholism treatment for individuals with specific genetics. Risks are associated with a potential increase in logistics costs due to geopolitics. The year-over-year commercial revenue dynamics for the rolling year demonstrate revenue trends, where the 0.00 level reflects the current magnitude.

ADIL (Adial Pharmaceuticals) riwayat Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 29.10.2026

Adial Pharmaceuticals (ADIL) - rincian metrik lan laporan keuangan

- nilai saham lan prakiraan konsensus rega:
Ringkesan analitik perusahaan:ADIL (Adial Pharmaceuticals, Inc.)
Produk dadi Adial

This indicator measures revenue dynamics over a rolling twelve-month period, allowing for a real-time assessment of trading momentum and the elimination of seasonal distortions when analyzing business scaling. The year-over-year sales volume growth trajectory for TTM on the GURU.Markets platform demonstrates the ability of Adial Pharmaceuticals (ADIL) to monetize its patents amidst strict FDA regulatory oversight and high barriers to entry in the addiction treatment niche.